U.S. pharma huge copyright scrapped two experimental weight loss products last 12 months—a at the time-day by day capsule, lotiglipron, due to elevated liver enzymes plus a 2 times-every day tablet, danuglipron, resulting from robust side effects—but CEO Albert Bourla has explained t